within Pharmacolibrary.Drugs.ATC.C;

model C02KX03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 6.833333333333332e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006833333333333333,
    Tlag           = 12.0,            
    Vdp             = 0.052,
    k12             = 12.5,
    k21             = 12.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C02KX03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Sitaxentan is an endothelin receptor antagonist developed for the treatment of pulmonary arterial hypertension (PAH). It selectively blocks the endothelin-A receptor. Sitaxentan was withdrawn globally due to liver toxicity concerns and is not currently approved or in clinical use.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics reported for adult patients with pulmonary arterial hypertension after oral dosing.</p><h4>References</h4><ol><li><p>Cross, DM, et al., &amp; Stavros, FL (2012). An evaluation of reproductive and developmental toxicity of sitaxentan (thelin) in rats. <i>Birth defects research. Part B, Developmental and reproductive toxicology</i> 95(5) 327–336. DOI:<a href=\"https://doi.org/10.1002/bdrb.21021\">10.1002/bdrb.21021</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22890981/\">https://pubmed.ncbi.nlm.nih.gov/22890981</a></p></li><li><p>MacIntyre, IM, et al., &amp; Webb, DJ (2008). Sitaxsentan sodium for pulmonary hypertension. <i>Drugs of today (Barcelona, Spain : 1998)</i> 44(8) 585–600. DOI:<a href=\"https://doi.org/10.1358/dot.2008.44.8.1239808\">10.1358/dot.2008.44.8.1239808</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18846270/\">https://pubmed.ncbi.nlm.nih.gov/18846270</a></p></li><li><p>Steiner, MK, &amp; Preston, IR (2008). Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension. <i>Vascular health and risk management</i> 4(5) 943–952. DOI:<a href=\"https://doi.org/10.2147/vhrm.s2270\">10.2147/vhrm.s2270</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19183742/\">https://pubmed.ncbi.nlm.nih.gov/19183742</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C02KX03;
